AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
The other two electric utility companies in the country are Sarawak Energy and Sabah Electricity. In 2013, Malaysia's total power generation capacity was over 29,728 megawatts. Total electricity generation was 140,985.01 GWh and total electricity consumption was 116,087.51 GWh. Energy production in Malaysia is largely based on oil and natural gas, owing to Malaysia's oil and natural gas reserves, which are the fourth largest in the Asia-Pacific region.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on NADH or NADPH with a quinone or similar compound as acceptor. The systematic name of this enzyme class is 2-hydroxy-1,4-benzoquinone:NADH oxidoreductase. Other names in common use include hydroxybenzoquinone reductase, 1,2,4-trihydroxybenzene:NAD oxidoreductase, and NADH:2-hydroxy-1,4-benzoquinone oxidoreductase.
On 4 December 2024, the Lebanese Health Ministry reported that since 7 October 2023, Israeli attacks killed 4,047 people, including 316 children and 790 women, and injured 16,638 others. Among the dead were at least 41 Lebanese Army soldiers and more than 200 medics. Several UNIFIL workers and peacekeepers were injured in numerous attacks by both Israel and Lebanese militias. By 25 November 2025, the Lebanese Health Ministry reported that Israeli attacks during the ceasefire had killed 331 people and injured 945. The UN said that at least 127 fatalities were civilians. At the height of the conflict in October 2024, more than 1.2 million Lebanese were displaced, including between 200,000 and 300,000 who fled into Syria.
Sources: en.wikipedia.org
== External links == "Adenosine Receptors: A1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2020-09-20. Retrieved 2007-10-25. Adenosine+A1+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ADORA1 genome location and ADORA1 gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P30542 (Adenosine receptor A1) at the PDBe-KB.
In 2016, Burger King signed a build-to-suit lease agreement on a new 150,000 square feet (14,000 m2) five-story headquarters building to be built at 5707 Blue Lagoon Drive, just down the street from its existing nine-story headquarters at 5505 Blue Lagoon Drive. This was slightly smaller than the 200,000 square feet (19,000 m2) it was leasing in its current headquarters building at the time. In 2018, Burger King moved into its new headquarters at 5707 Blue Lagoon Drive. As of August 2024, the Burger King system operates more than 18,700 locations in more than 100 countries and U.S. territories.
For colorectal cancer, a systematic review of randomized clinical trials and the large SELECT trial reported no statistically significant change in relative risk. The Women's Health Study reported no significant differences for incidences of all types of cancer, cancer deaths, or specifically for breast, lung or colon cancers. Potential confounding factors are the form of vitamin E used in prospective studies and the amounts. Synthetic, racemic mixtures of vitamin E isomers are not bioequivalent to natural, non-racemic mixtures, yet are widely used in clinical trials and as dietary supplement ingredients. One review reported a modest increase in cancer risk with vitamin E supplementation while stating that more than 90% of the cited clinical trials used the synthetic, racemic form dl-alpha-tocopherol.
George Oliver Gilham, First Secretary (Works), British High Commission, New Delhi. Joan Doreen Gol. For charitable and welfare services in Texas, United States of America. Rose Yin-chee Goodstadt, . For services to public health and welfare, Hong Kong. Louise Elizabeth Higham, Head, British Council Office, Barcelona. Marjone Helen Hoare. For services to literature and the island heritage, Gibraltar. Ann Hui On-wah. For services to the performing arts, Hong Kong. Norman Peter Jackson, Field Director, Save The Children Fund, Khartoum. Neil Alexander Kernohan, lately Vice-Consul, British Interests Section, Italian Embassy, Tripoli. James Kwan Kin-cheung. For public service, Hong Kong. Lee Lai-shan. For services to sport, Hong Kong. Andrew Leung Kwan-yuen. For services to the textile industry, Hong Kong. Leung Shou-chun, Principal Government Land Surveyor, Hong Kong. Li Shai-hung. For public service, Hong Kong. Simon Li Pak-ho, , Senior Assistant Director of Housing, Hong Kong. Sarah Mary Liao Sau-tung, . For services to consumer and environmental affairs, Hong Kong. Lo Tin-hoi, Management Assistant, British Trade Commission, Hong Kong. Dora Amy Logan. For services to the British community, Argentina. Fiona MacCallum, Attaché, HM Embassy, Riga. Allison Mary Marriott, lately Third Secretary, UK Delegation to the Western European Union, Brussels. Tanya Bonsovna Matthews. For services to broadcasting and journalism, Tunisia. Florenz Elaine Webbe Maxwell. For services to the Girl Guides and education in Bermuda.
Sources: en.wikipedia.org
When her husband died in 1882 she told the Boston Globe that malicious animal magnetism had killed him. While Eddy argued that reality was entirely spiritual (and therefore entirely good), it remained true that human beings were affected by their belief in evil, which meant it had power, even if the power was an illusion. Evil was "like a bankrupt to whom credit is still granted", writes Wilson. To defend herself against it, Eddy organized "watches", during which students (known as mental or metaphysical workers) would give "adverse treatment" to her enemies. This was called "taking up the enemy in thought". According to former students, Eddy would tell them to say (often with Richard Kennedy in mind): "You are affected as you wish to affect me. Your evil thought reacts upon you," then to call Kennedy bilious, consumptive or poisoned by arsenic. Eddy set up what she called a secret society of her students (known as the P. M., or private meeting) to deal with malicious animal magnetism, but she said that the group only met twice. In her later years, Wilson writes, Eddy came to see animal magnetism as an impersonal force and concluded that individuals ought not to be "taken up in thought". From 1890 she felt that her students were focusing on it too much, and thereafter public discussion of malicious animal magnetism declined, although Gottschalk adds that it continued to play an important role in the teaching of Christian Science. Adam H.
=== Ed Conner === Ed Conner is played by Ned Beatty. Ed is Dan's father, a charming traveling salesman who always brings presents for the grandchildren. Dan has a troubled history with his father, and Roseanne tries to keep the peace between the two. The family likes Ed, but Dan grew up feeling neglected with Ed seldom being home and his mother's mental illness, in addition to verbal slights that Ed targets towards Dan (e.g., when Dan questions Ed dating Crystal, Ed makes a rude crack about Dan being "interested" in Crystal). It usually takes little to no time for Dan to become annoyed by his father's presence. All this was unknown to Dan until Crystal revealed it to Roseanne. Ed hoped to provide Dan with at least one stable parent as he would often be gone on sales trips during Dan's adolescence. He wants to learn from his past actions and be a better father and husband. He loves his son despite their troubled relationship, and also loves the rest of his family. He marries Crystal and has two children with her (Ed Jr. and Angela), who are significantly younger than their half-brother, Dan. He is said to have died in The Conners; it appears he was no longer with Crystal and was living alone.
== Galleries and gardens == The birthplace of the MNHN and a large part of its modern collections are found in five galleries in the Jardin des Plantes. These are the Gallery of Evolution; the Gallery of Mineralogy and Geology; the Gallery of Botany; the Gallery of Palaeontology and Comparative Anatomy, and the Laboratory of Entomology.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.